196170.KQ实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 14:30):

Stats
今日成交量	961 336
平均成交量	1.93M
市值	9 389.49B
EPS	KRW0 ( 2024-03-17 )
下一个收益日期	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW314.81 (0.18%)

音量相关性

長: -0.45 (neutral)

短: 0.35 (neutral)

Signal:(46.488) Neutral

ALTEOGEN Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ALTEOGEN Inc. 相关性 - 货币/商品

0.19
( neutral )

-0.03
( neutral )

0.02
( neutral )

0.21
( neutral )

-0.19
( neutral )

ALTEOGEN Inc. 财务报表

Annual	2023
营收:	KRW96.52B
毛利润:	KRW82.23B (85.19 %)
EPS:	KRW-65.27

FY	2023
营收:	KRW96.52B
毛利润:	KRW82.23B (85.19 %)
EPS:	KRW-65.27

FY	2022
营收:	KRW28.81B
毛利润:	KRW9.41B (32.67 %)
EPS:	KRW-158.85

Financial Reports:

No articles found.

ALTEOGEN Inc.

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; and ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology. The company has a strategic alliance with Kissei Pharmaceutical to develop Aflibercept that has completed pre-clinical trial; and Cristalia for the development of Trastuzumab, which is in the Phase II clinical trial for the treatment of breast cancer. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.